PARP inhibitors – theoretical basis and clinical application

Journal Title: Advances in Hygiene and Experimental Medicine - Year 2012, Vol 66, Issue 0

Abstract

Poly-ADP-ribose polymerases (PARP) are involved in a number of processes that are vital for every living cell. Once activated by the presence of DNA damage they trigger poly-ADP-ribosylation of various proteins which are crucial for DNA repair, preserving of genom integrity, regulation of transcription, proliferation and apoptosis. PARP1, which is the best known enzyme of PARP protein family, plays a role in single-strand breaks (SSB) repair. Decrease of its activity results in accumulation of single strand DNA breaks (SSB) which leads as a consequence to double- strand breaks (DSBs). This disorder is particularly harmful to cells with deficiency of BRCA1/2 protein which is involved in repair of DNA double-strand breaks. This phenomenon is an example of “synthetic lethality” concept and contributes to research on application of PARP inhibitors in treatment of cancers associated with BRCA1/2 protein defect (breast or ovarian cancer). Noticed synergism between PARP inhibitors and genotoxic chemotherapy or radiotherapy determined another direction of research on application of these medicaments. After promising results of phase I and II trials with most commonly investigated PARP inhibitors – iniparib and olaparib- which recruited patients with triple negative breast cancer and ovarian cancer, further studies started. This paper presents theoretical basis of PARP inhibitors action as well as critical review of most important clinical trials of these medicaments.

Authors and Affiliations

Sylwia Dębska, Joanna Kubicka, Rafał Czyżykowski, Maja Habib, Piotr Potemski

Keywords

Related Articles

Evolution of sanitary-epidemiological services in Poland in the years 1944-2014

This paper presents the history of sanitary-epidemiological services in the context of the health, economic and socio-political situation in Poland in the years 1944-2014, with a critical analysis of legal restraints, ef...

Naturalne związki zaangażowane w kontrolę masy tkanki tłuszczowej w badaniach in vitro

Światowa Organizacja Zdrowia (WHO) uznała otyłość za epidemię XXI wieku. Otyłość to patologiczne nagromadzenie tkanki tłuszczowej w ustroju uwarunkowane wieloma czynnikami: metabolicznymi, endokrynologicznymi, genetyczny...

Vaccinomics and adversomics as new trends in vaccinology

Currently used vaccines have been developed based on experimental pre-clinical and clinical trials. Although the widespread availability of vaccines is one of the greatest achievements in public health, the selection of...

Genetyka zespołów otępiennych. Część 2: Biologia choroby Alzheimera

Mózgi chorych z chorobą Alzheimera (AD) cechuje atrofia kory mózgowej połączona ze skurczeniem się jej zakrętów, rozszerzeniem bruzd oraz powiększeniem komór. Hipokamp i kora endorinalna są zazwyczaj pierwszymi uszkodzon...

Download PDF file
  • EP ID EP66698
  • DOI -
  • Views 170
  • Downloads 0

How To Cite

Sylwia Dębska, Joanna Kubicka, Rafał Czyżykowski, Maja Habib, Piotr Potemski (2012). PARP inhibitors – theoretical basis and clinical application. Advances in Hygiene and Experimental Medicine, 66(0), 311-321. https://europub.co.uk./articles/-A-66698